- Home
- SF vs EXAS Comparison
SF vs EXAS Comparison
Compare SF & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SF
- EXAS
- Stock Information
- Founded
- SF 1890
- EXAS 1995
- Country
- SF United States
- EXAS United States
- Employees
- SF N/A
- EXAS N/A
- Industry
- SF Investment Bankers/Brokers/Service
- EXAS Medical Specialities
- Sector
- SF Finance
- EXAS Health Care
- Exchange
- SF Nasdaq
- EXAS Nasdaq
- Market Cap
- SF 9.8B
- EXAS 10.7B
- IPO Year
- SF N/A
- EXAS N/A
- Fundamental
- Price
- SF $107.33
- EXAS $53.86
- Analyst Decision
- SF Hold
- EXAS Strong Buy
- Analyst Count
- SF 8
- EXAS 20
- Target Price
- SF $105.14
- EXAS $70.16
- AVG Volume (30 Days)
- SF 662.6K
- EXAS 2.8M
- Earning Date
- SF 07-23-2025
- EXAS 07-30-2025
- Dividend Yield
- SF 1.72%
- EXAS N/A
- EPS Growth
- SF 19.51
- EXAS N/A
- EPS
- SF 5.24
- EXAS N/A
- Revenue
- SF $5,030,597,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- SF $7.38
- EXAS $14.58
- Revenue Next Year
- SF $9.94
- EXAS $12.75
- P/E Ratio
- SF $20.39
- EXAS N/A
- Revenue Growth
- SF 14.86
- EXAS 11.57
- 52 Week Low
- SF $73.27
- EXAS $39.97
- 52 Week High
- SF $120.64
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- SF 77.41
- EXAS 51.90
- Support Level
- SF $96.54
- EXAS $52.60
- Resistance Level
- SF $98.33
- EXAS $55.09
- Average True Range (ATR)
- SF 2.21
- EXAS 2.15
- MACD
- SF 0.80
- EXAS -0.02
- Stochastic Oscillator
- SF 98.04
- EXAS 51.57
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.